DC
BMY icon

Davenport & Co’s Bristol-Myers Squibb BMY Stock Holding History

Davenport & Co’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,318,900
Closed -$67.7M – 1111
2023
Q4 		$67.7M Buy
+1,318,900
New +$69.2M 0.46% 80

Other funds holding BMY

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co's BMY Position: Q2 2026 in Review

Davenport & Co reduced its Bristol-Myers Squibb (BMY) stake by 6.4% in Q2 2026, selling an estimated $475K and leaving 120,870 shares worth $6.97M. The position accounts for 0.03% of the portfolio, ranked #302.

Davenport & Co first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $138M in Q1 2025. 706 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Davenport & Co held 120,870 shares of Bristol-Myers Squibb worth $6.97M as of Q2 2026.
  • Davenport & Co sold 8,270 Bristol-Myers Squibb shares in Q2 2026, an estimated $475K.
  • Bristol-Myers Squibb made up 0.03% of Davenport & Co's portfolio in Q2 2026, its #302 holding.
  • Davenport & Co first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Davenport & Co's Bristol-Myers Squibb position peaked at $138M in Q1 2025.
  • 706 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.